Research programme: bryostatin analogues - GPC Biotech
Alternative Names: Bryologs research programme - GPC Biotech; Bryostatin analogues research programme - GPC BiotechLatest Information Update: 11 Mar 2004
At a glance
- Originator Stanford University
- Developer GPC Biotech Inc
- Class
- Mechanism of Action Protein kinase C stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Cancer
Most Recent Events
- 11 Mar 2004 Discontinued - Preclinical for Cancer in USA (unspecified route)
- 31 Jul 2002 Preclinical trials in Cancer in USA (unspecified route)